Outlook Therapeutics, Inc.
OTLK
$1.68
-$0.01-0.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 62.26% | 62.26% | 9.06% | -66.12% | -58.95% |
| Gross Profit | -62.26% | -62.26% | -9.06% | 66.12% | 58.95% |
| SG&A Expenses | 49.91% | 35.48% | 12.25% | 12.19% | 12.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.69% | 73.75% | 34.97% | 12.13% | 11.82% |
| Operating Income | -27.69% | -73.75% | -34.97% | -12.13% | -11.82% |
| Income Before Tax | 113.27% | 9.10% | -27.78% | -55.88% | -178.21% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | -22.22% | -22.22% |
| Earnings from Continuing Operations | 113.27% | 9.10% | -27.78% | -55.87% | -178.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 113.27% | 9.10% | -27.78% | -55.87% | -178.20% |
| EBIT | -27.69% | -73.75% | -34.97% | -12.13% | -11.82% |
| EBITDA | -27.66% | -73.74% | -34.87% | -12.13% | -11.93% |
| EPS Basic | 111.92% | -28.94% | -40.84% | -56.97% | -127.31% |
| Normalized Basic EPS | 115.90% | 63.62% | 35.16% | 15.13% | -41.73% |
| EPS Diluted | 87.55% | -99.04% | -99.51% | -112.17% | -127.33% |
| Normalized Diluted EPS | 113.91% | 59.75% | 31.99% | 12.20% | -41.73% |
| Average Basic Shares Outstanding | 92.10% | 65.32% | 48.32% | 32.05% | 14.81% |
| Average Diluted Shares Outstanding | 96.33% | 69.67% | 52.82% | 36.73% | 14.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |